Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 78Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
Can Cimetidine, a common antacid, be repurposed for cancer?
A clinical study published in one of the leading oncology journals, Cancer, shows that Cimetidine can be synergized with other drugs, including existing therapies, and that its potential as an anti-cancer therapeutic should be explored much further. Cimetidine has historically been used to treat indigestion through its ability to block histamine receptors in the gut. A widely available generic, Cimetidine was launched by GlaxoSmithKline under the trade name Tagamet. In some countries, like the USA, the product is available over-the-counter and is used for treating ulcers and heartburn.  The authors in their research share abundant pre-clinical and clinical evidence which demonstrate the therapeutic effects of Cimetidine in a range of cancers, especially cancers of the gastrointestinal tract, renal cell carcinoma and melanoma.  Recycling old drugs makes drug repositioning, or repurposing, an attractive form of drug discovery and accounts for approximately 30% of the newly approved drugs and vaccines by the FDA (US Food and Drug Administration) in recent years.   An enormous source of profits for the pharmaceutical industry and one of the most famous examples of drug repositioning is Viagra. Viagra was originally identified in connection with angina, and was successfully repositioned for erectile dysfunction.  The ReDO project (the repurposing drugs in oncology project), an international global collaboration of researchers, is dedicated to promoting common medicines such as mebendazole (for threadworm infections), nitroglycerin (used to treat angina), itraconazole (broadly used anti-fungal), diclofenac (a commonly prescribed painkiller) and clarithromycin (an antibiotic) as anti-cancer therapies.  The team of researchers combines the expertise of the Anticancer Fund, which is focused on expanding cancer treatment options by repurposing drugs, and Global Cures, a non-profit, medical research organization dedicated to curing patients with cancer.  The authors believe that, should positive results be obtained in an underway clinical trial that is studying the effect of Cimetidine in Colorectal Cancer, the focus on the potential of Cimetidine as an anti-cancer therapeutic will be re-ignited.  Drug Repositioning has been subject to extensive studies over the past few years and there are numerous examples of successful repositioning of products. Success of the ReDO project would allow cheaper access to solutions in the fight against cancer and once again support the case of looking at existing drugs instead of only focusing on novel, and potentially expensive treatments. It indeed brings a lot of hope for cancer patients since many existing treatments carry unwelcome side effects, and so existing drugs whose effects are already well understood and documented may well be utilized to assist treatment without the risk and without the massive cost and side effect implications.  

Impressions: 2386

https://www.pharmacompass.com/radio-compass-blog/can-cimetidine-a-common-antacid-be-repurposed-for-cancer

#Phispers by PHARMACOMPASS
12 Mar 2015

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/08/22/2934230/0/en/Inhibitor-Therapeutics-Inc-Provides-Update-on-its-Clinical-Development-Plan.html

GLOBENEWSWIRE
22 Aug 2024

https://www.prnewswire.com/news-releases/pulmatrix-announces-publication-on-physiologically-based-pharmacokinetic-modelling-of-potential-drug-drug-interactions-with-pur1900-orally-inhaled-itraconazole-301907549.html

PR NEWSWIRE
23 Aug 2023

https://www.biospectrumasia.com/news/25/19206/indian-firm-intas-pharma-makes-breakthrough-in-antifungal-therapy-domain.html

BIOSPECTRUMASIA
13 Oct 2021

https://www.biospace.com/article/releases/gannex-announces-positive-topline-results-from-the-u-s-phase-i-trial-of-drug-drug-interactions-in-healthy-subjects-and-pharmacokinetics-in-patients-with-nafld-for-its-thr%ce%b2-agonist-asc41/

BIOSPACE
07 Sep 2021

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-21-2021-1619072775.pdf

FDA
22 Apr 2021

https://mainichi.jp/english/articles/20201215/p2a/00m/0na/006000c

JP
15 Dec 2020